Introduction
Dendritic cells (DCs) are innate professional antigen-presenting cells (APCs) that initiate and regulate adaptive immunity.
1,2 DCs control T-cell reactivity by coordinating display of Ag to T cells in the context of major histocompatibility class molecules with the delivery of costimulation and cytokines that dictate T-cell differentiation and function. Although costimulatory molecules support T-cell responses, coinhibitory molecules restrain T-cell reactivity. Our understanding of the precise molecular mechanisms regulating expression of proinflammatory vs regulatory signals by DCs remains unclear.
B7-homolog 1 (B7-H1, programmed death 1 [PD-1] ligand 1; CD274) is a B7 family coinhibitory molecule expressed on DCs in a regulated manner that binds to PD-1 (CD279) on activated T cells, thereby reducing their proliferation and proinflammatory cytokine production. 3, 4 The B7-H1/PD-1 pathway plays a crucial role in the maintenance of peripheral tolerance.
5 B7-H1 stimulates T-cell secretion of anti-inflammatory interleukin (IL) 10 6 and promotes the induction, maintenance, and function of regulatory T cells (Tregs) from naive T cells. 7 Importantly, the precise upstream mechanisms regulating B7-H1 expression remain elusive, and the differential regulation of costimulatory vs coinhibitory molecule expression is poorly understood, despite their central role in the activation and constraint of adaptive T-cell responses by DCs.
Mammalian target of rapamycin (mTOR) is a highly conserved, serine/threonine kinase that controls APC and T-cell function. 8, 9 The mTOR kinase performs the catalytic function of 2 independent complexes: mTOR complex (mTORC) 1 and mTORC2. 10, 11 mTORC1 consists of mTOR, regulatory associated protein of mTOR (raptor), mammalian lethal with Sec13 protein 8 (mLST8), and proline-rich substrate of Akt of 40 kD (PRAS40), whereas mTORC2 contains mTOR, rapamycin (RAPA)-insensitive companion of mTOR (rictor), mLST8, mSIN1, and protein associated with rictor (PROTOR). 12 Although RAPA is a potent allosteric inhibitor of mTORC1, it exerts little activity against RAPA-insensitive mTORC2. 10, 11 However, novel, highly selective adenosine triphosphate (ATP)-competitive active site mTOR inhibitors that block both mTOR-containing complexes have revealed RAPA-resistant mTORC1 and mTORC2 signaling in nonimmune cells. 13, 14 mTORC1 inhibition suppresses conventional DC maturation and promotes their tolerogenicity. 2, 8, 15 Conversely, RAPA has paradoxical, proinflammatory effects on DCs, including increased secretion of IL12p70 and IL-1b, with concomitant reduced secretion of IL-10 and expression of B7-H1. [16] [17] [18] [19] [20] [21] These effects on DCs are mediated by augmentation of nuclear factor kB (NF-kB) activity and reduction in signal transducer and activator of transcription (STAT) 3 activity. 17, 20, 21 RAPA-insensitive mTORC2 regulates the actin cytoskeleton in nonimmune cells, 10, 11 and insight is emerging into its function in T lymphocytes. Selective deletion of mTORC2 in T cells impairs their differentiation into T helper (Th) 1 and Th2 22 or only Th2 subsets. 23 In contrast to the well-defined role of mTORC1, little is known about the function of mTORC2 in APCs or innate immunity. In this study, we sought to define the role of RAPA-resistant mTOR in molecular regulation of the ability of DCs to promote T-cell immunity.
We find that RAPA-resistant mTOR negatively regulates conventional DC STAT3-mediated IL-10 and B7-H1 expression. Deletion of the mTORC2 subunit rictor had the opposite effect, suggesting that residual RAPA-resistant mTORC1 activity or dual mTORC1 and 2 inhibition mediates this central anti-inflammatory pathway in DCs. Enhanced STAT3 activation in DCs exposed to ATP-competitive mTOR inhibitors correlated with a reduction in suppressor of cytokine signaling (SOCS) 3. Functionally, mTORC1-inhibited DCs were unable to stimulate proliferation of forkhead box P3 (Foxp3 -) effector T cells (Teffs), whereas ATPcompetitive mTOR inhibition additionally promoted the induction of Foxp3
1 Tregs in a B7-H1-dependent manner that also required IL-1b. These data reveal a novel, RAPA-resistant anti-inflammatory pathway in DCs that regulates IL-10 and B7-H1 and identifies divergent regulation of T eff and T reg responses by DCs due to RAPA-sensitive and RAPA-resistant mTOR. ) and ROSA26-CreERT2 were maintained at the University of Pittsburgh. WYE-125132 (50 mg/kg 24 intraperitoneally; Selleck Chemicals) was dissolved in dimethylsulfoxide (DMSO) and administered in a vehicle composed of 5% Tween 80 and 54% polyethylene glycol (Sigma-Aldrich; average M n 300) at the time of lipopolysaccharide (LPS) injection (Escherichia coli 0111:B4; Sigma-Aldrich; 100 mg/kg intraperitoneally). The work performed in this study was covered under University of Pittsburgh Institutional Animal Care and Use Committee (IACUC) protocol 1102281.
Methods

Animals and drug administration
DC differentiation, purification, and stimulation
DCs were generated from BM cells, as described 19, 25 using recombinant (r) mouse granulocyte macrophage-colony-stimulating factor and r mouse IL-4 (both 1000 U/mL; R&D Systems). On day 8 of culture, myeloid DCs were selected from nonadherent cells by anti-CD11c immunomagnetic bead purification (Miltenyi Biotec). 
Flow cytometric analyses
Cell surface and intracellular staining was performed as described. 19, 25 Fluorochrome-conjugated monoclonal antibodies were purchased from eBioscience, BD Bioscience, or Biolegend. P-STAT3 quantification by flow cytometry was performed as described. 20 Data were acquired using an LSR II or LSR Fortessa flow cytometer (BD Bioscience) and analyzed using FlowJo 8.8.6 (Tree Star). Percent P-STAT3 positive cells was determined using Overton Subtraction (FlowJo) by comparing experimental samples with corresponding control samples stained with secondary antibody (Ab) only.
Mixed leukocyte reaction (MLR)
ϒ-irradiated (20 Gy) DCs (B6; 1 3 10 4 ) were used as stimulators in 5-day allogeneic MLR as described. 27 Normal CD4 
Cytokine quantification
Enzyme-linked immunosorbent assays were performed on cell-free DC supernatants according to the manufacturer's instructions to quantify IL-12p40 and IL-6 (Biolegend). IL-1b was quantified by cytometric bead array (BD Bioscience) according to the manufacturer's protocol.
Tamoxifen induction of Cre recombinase
One hundred nanomolar (Z)-4-hydroxytamoxifen (4OHT; Sigma-Aldrich) was added to BM cultures on day 0 to delete FoxO transcription factors from FoxO1/3/4 fl/fl 3 ROSA26-CreERT2 BM-derived DCs. Tamoxifen (15 mg/mL; Sigma-Aldrich) was administered intraperitoneally in sunflower seed oil (Sigma-Aldrich) every 2 days for 3 doses to rictor fl/fl 3 ROSA26-CreERT2 mice. BM cells were harvested from these mice 7 days later and cultured to generate rictor 2/2 BM-derived DCs.
Immunoblot
Immunoblotting was performed on DC lysates as described 19 ,25 using primary Abs from Cell Signaling, with the exception of glyceraldehyde-3-phosphate dehydrogenase (Novus Biologicals) and SOCS5 (Thermo Scientific). Densitometry was performed using ImageJ (National Institutes of Health).
Statistical analyses
Results are expressed as means 11 standard deviation. The unpaired, 2-tailed Student t test was used to determine the significance of differences between means (GraphPad Prism).
Results
RAPA-resistant mTOR is a negative regulator of conventional DC B7-H1 expression
We first examined the surface phenotype of B6 BM-derived conventional DCs propagated under conditions of either mTORC1 inhibition with RAPA or mTORC1 and 2 inhibition with the ATPcompetitive mTOR inhibitor Torin1. As reported previously for RAPA, 16 DCs differentiated in Torin1 were small and homogenous compared with control DCs ( Figure 1A ). Although mTOR inhibition did not affect CD11c 1 DC differentiation ( Figure 1C ), both RAPA and Torin1 reduced the DC yield from BM cell cultures ( Figure 1D ). In agreement with previous studies, 17, 20 RAPA reduced the expression of CD80, CD86, B7-H1, and B7-DC on both unstimulated and LPSstimulated DCs ( For personal use only. on June 12, 2017. by guest www.bloodjournal.org From cell-derived DCs; however, B7-H1 expression was spared by Torin1, resulting in significantly higher expression than on RAPAexposed DCs (supplemental Figure 2) . AZD8055, another ATP-competitive mTOR inhibitor, similarly increased B6 DC B7-H1 expression ( Figure 1F ; supplemental Figure 3A ), thus confirming that B7-H1 upregulation was due to on-target mTOR inhibition. Surprisingly, rictor 2/2 DCs lacking mTORC2 activity displayed diminished B7-H1 expression following LPS stimulation ( Figure 1G -H). DC differentiation was not affected, whereas the DC yield was reduced slightly in rictor
BM cultures (supplemental Figure 3B-C) . Together, these data suggest that RAPA-resistant mTORC1 is a negative regulator of DC B7-H1 expression downstream of TLR4, whereas mTORC2 is a positive regulator of B7-H1 expression. Further analysis revealed that enhanced B7-H1 expression on Torin1-conditioned DCs occurred predominantly on immature CD86 lo cells (Figure 2A-B) . Similarly, AZD8055-conditioned DCs were mainly CD86 lo B7-H1 hi (supplemental Figure 3A ,D-E). The ratio of coinhibitory (B7-H1) to costimulatory (CD86) B7 family molecule expression was enhanced on Torin1-and AZD8055-conditioned DCs to a greater extent than on RAPA-conditioned DCs, with or without LPS stimulation ( Figure 2C ; supplemental Figure 3F ). Human monocyte-derived DCs, but not CD34 1 cellderived DCs, differentiated in Torin1 exhibited a trend toward an elevated ratio of B7-H1 to CD86 expression compared with those differentiated in RAPA (supplemental Figure 2C ,F).
STAT3 but not IRF-1 is required for upregulation of B7-H1 on DCs by Torin1
The B7-H1 promoter contains 2 IRF-1 binding sites that are required for constitutive expression and interferon ϒ-induced upregulation of B7-H1 in cancer cell lines. 28 We analyzed B7-H1 expression on wild-type and IRF-1-null Torin1-conditioned DCs, but IRF-1 was not required for augmented DC B7-H1 expression (Figure 3A STAT3 binds the B7-H1 promoter and is required for B7-H1 expression by lymphoma cell lines. 29 Importantly, STAT3 has also been identified as a critical regulator of B7-H1 on human APC. 30 STAT3 inhibition reversed enhanced B7-H1 expression ( Figure 3C-D) , eliminated concomitant CD86 lo B7-H1 hi expression (supplemental Figure 4D-E) , and reduced the B7-H1/CD86 ratio on MFI divided by the normalized CD86 MFI for the indicated culture conditions. n $ 5 experiments for all data presented. *, # P , .05 when compared with DMSO and RAPA, respectively. BLOOD
org From
Torin1-conditioned DCs (supplemental Figure 4F ). These data demonstrate that enhanced DC B7-H1 expression induced by Torin1 occurs through an IRF-1-independent and STAT3-dependent pathway.
FoxO transcription factors mediate immune homeostasis 31 and control the ability of DCs to limit T-cell expansion following viral infection. 32 FoxO promotes STAT3 activity, and FoxO3 transcription correlates with elevated B7-H1 expression by tumorassociated DCs.
33 Torin1-conditioned DCs were generated from FoxO1/3/4 2/2 BM cells by exposing FoxO1/3/4 fl/fl 3 ROSA26-CreERT2 BM cells to 4OHT. 34 Deletion of FoxO3a was confirmed by immunoblot (data not shown). FoxO was not required for B7-H1 upregulation by Torin1 ( Figure 3E-F) , thus suggesting a STAT3-dependent but FoxO-independent mechanism of RAPAresistant mTOR negative regulation of B7-H1.
ATP-competitive mTOR inhibition enhances STAT3 signaling by reducing SOCS3 expression
Studies with RAPA have implicated mTORC1 as a positive regulator of STAT3 in DCs 17, 20 ; however, reduced IL-10 secretion by RAPA-exposed DCs leads to reduced autocrine STAT3 activation. 21 DCs were preincubated with RAPA or Torin1 for 2 hours before LPS stimulation (hereby referred to as "short-term" mTOR inhibition). As reported, 12 RAPA abolished mTORC1 signaling (P-S6K T389), but only Torin1 blocked mTORC2 signaling (P-Akt S473; Figure 4A ). Both short-term RAPA and Torin1 inhibited STAT3 phosphorylation following LPS stimulation ( Figure 4B-C) . In contrast, DC differentiated in the presence of Torin1, but not RAPA, from day 2 to day 8 (hereby referred to as "RAPA-or Torin1-conditioned DC") demonstrated augmented STAT3 phosphorylation 3 hours after LPS stimulation ( Figure 4D-F) . SOCS proteins regulate cytokine signaling by inhibiting Janus kinase (JAK)-STAT pathways. 35 RAPA conditioning led to augmented SOCS1 and SOCS5, which are negative regulators of STAT1 36 and STAT6, 37 respectively ( Figure 4G ). Torin1 suppressed expression of the key STAT3 negative regulator SOCS3 ( Figure 4E,  G) . 38 As such, we make the novel observation that extended mTORC1 and 2 inhibition by Torin1, but not mTORC1 inhibition by RAPA, downregulates SOCS3 and enhances STAT3 signaling.
Rictor 2/2 DCs were unable to phosphorylate Akt S473;
however, mTORC1 signaling was intact ( Figure 4H ). These cells exhibited diminished P-STAT3 following LPS stimulation, and there was no change in SOCS3 expression ( Figure 4I-J) . Importantly, these data establish that RAPA-resistant mTORC1 negatively regulates STAT3, whereas mTORC2 is a positive regulator of STAT3.
RAPA-resistant mTOR inhibition augments IL-10 production, but it is not required for B7-H1 upregulation STAT3 phosphorylation occurs late (1-3 hours) after LPS stimulation of DCs (Figure 4 ), suggesting autocrine signaling that induces phosphorylation. Autocrine IL-10 signaling is required for STAT3 phosphorylation following LPS stimulation. 21 IL-10 production was increased markedly in B7-H1 hi Torin1-conditioned IL-10-gfp reporter DCs (Figure 5A,C) . The IL-10 mean fluorescence intensity (MFI) was increased in Torin1-conditioned DCs compared with RAPA-conditioned and control DCs (Figure 5B,D) . Both RAPAand Torin1-conditioned DCs secreted increased IL-12/23p40 ( Figure 5E ). Rictor 2/2 DCs also secreted elevated IL-12p40 (data not shown). IL-6 and IL-1b secretion by DCs after LPS stimulation was reduced and increased, respectively, by RAPA, but unaffected by Torin1 ( Figure 5F -G). IL-6, IL-10, IL-23, and IL-27 all stimulate STAT3 phosphorylation. [38] [39] [40] Neither autocrine IL-6 nor IL-10 was required for enhanced B7-H1 expression by Torin1 on control or LPS-stimulated DCs ( Figure 5H-K) . Autocrine IL-23 and IL-27 were also not required, as determined using IL-12/23p40 2/2 and Ebi3 2/2 BM cell cultures, respectively (supplemental Figure 5A-D) . Collectively, these results identify a RAPA-resistant mTOR pathway that coregulates B7-H1 and IL-10 expression that does not depend on autocrine cytokine stimulation.
DC mTORC1 promotes T eff expansion, whereas RAPA-resistant mTOR restrains T reg induction via B7-H1
We next sought to determine how ATP-competitive mTOR inhibition modulates the T-cell stimulatory function of DCs. RAPA reduces the T-cell stimulatory capacity of DCs. 15, 16, 19, 27, 41 Torin1 shared this ability, although its effect was less than that of RAPA ( Figure 6A-B) . Although B7-H1 has been shown to restrain T-cell proliferation, 3 B7-H1 2/2 RAPA-DCs that express low CD80 and CD86 were less stimulatory than wild-type DCs ( Figure 6A-B) . These data are in agreement with early reports describing a T-cell proliferation-promoting effect of B7-H1. B7-H1 is a key regulator of T reg induction and function. 7 Because Torin1-conditioned DCs express elevated levels of B7-H1, we determined their ability to induce Tregs ( Figure 6C-F) . Torin1-conditioned DCs induced a significantly greater frequency of Tregs compared with control and RAPA-conditioned DCs ( Figure 6C-D) . Enhanced induction of Tregs by Torin1-conditioned DCs was dependent on B7-H1 ( Figure 6C-D) but independent of PD-1 (supplemental Figure 6A-B) . Although Torin1-conditioned For personal use only. on June 12, 2017. by guest www.bloodjournal.org From In some experiments, transforming growth factor b (TGFb) (10 ng/mL) was added at the start of culture as a positive control, and T cells without DC stimulators were included as a negative control.
DCs made increased IL-10 ( Figure 5A-D) , it was not required for their ability to induce Tregs (supplemental Figure 6A-B) . Neither genetic deletion nor neutralization of B7-H1 reduced T reg induction by control DCs (Figure 6C-D; supplemental Figure 6A-B) . The absolute number of Tregs induced by RAPA-conditioned DCs was reduced dramatically compared with control (supplemental Figure 6C ). Torin1-conditioned DCs induced a greater number of Tregs compared with RAPA-conditioned DCs, which was reduced in the absence of B7-H1 (supplemental Figure 6C) . CFSE dilution profiles of Foxp3 1 and Foxp3 -T cells were used to determine the relative contribution of inhibition of T eff (Foxp3 -) proliferation to induction of Tregs ( Figure 6E-F) . Consistent with our previous report, 27 RAPA-conditioned DCs stimulated Teffs poorly but stimulated CFSE lo Foxp3 1 T cells similarly to control DCs ( Figure 6E-F) . Torin1-conditioned DCs also stimulated Teffs less than control DCs; however, they approximately doubled the frequency of CFSE lo Foxp3 1 T cells ( Figure 6E-F ). These data demonstrate that ATP-competitive mTOR inhibition in DCs enhances their ability to induce Tregs in a B7-H1-dependent manner and augment CFSE lo Foxp3 1 T cells, whereas RAPAconditioned DCs specifically reduce proliferation of Teffs without affecting CFSE lo Foxp3 1 T cells.
There is evidence that IL-1b promotes T reg induction 42 and mTORC1 regulates IL-1b production by DCs. 16, 18 Although Torin1 did not alter IL-1b secretion by DCs ( Figure 5G Figure 6D -F). These data suggest that B7-H1 and IL-1b act cooperatively to promote T reg induction by Torin1-conditioned DCs.
ATP-competitive mTOR inhibition elevates DC B7-H1 expression in vivo and augments their ability to induce Tregs
To determine if RAPA-resistant mTOR modulates DC B7-H1 expression in a more physiological setting, we investigated in vivo modulation of DCs by ATP-competitive mTOR inhibition. WYE-125132 is an ATP-competitive mTOR inhibitor with in vivo bioavailability. 24 We first verified that WYE-125132 augmented DC B7-H1 expression while reducing CD86 expression in vitro ( Figure 7A-D) . When given as a single dose at the time of LPS administration, WYE-125132 enhanced splenic DC B7-H1 expression while reducing CD86 expression ( Figure 7E-G) . Furthermore, the ratio of B7-H1 to CD86 expression was increased ( Figure 7H ). These DCs augmented T reg induction ex vivo compared with control DCs (Figure 7I-J) . Together, these findings confirm that RAPA-resistant mTOR controls B7-H1 expression and modulates the ability of DCs to induce Tregs in vivo.
Discussion
Herein we describe a novel RAPA-resistant and mTORC2-independent signaling pathway in conventional DCs that controls B7-H1 and IL-10 expression downstream of TLR4. This novel signaling network coordinates the ability of DCs to stimulate T eff and T reg responses. DCs conditioned in ATP-competitive mTOR inhibitors dose-dependently and selectively upregulated B7-H1 expression. Elevated IL-10 production by Torin1-conditioned DCs was found in a B7-H1 hi population. B7-H1 upregulation by Torin1 8, 43 RAPA is a potent and selective mTORC1 inhibitor; however, prolonged exposure can inhibit mTORC2 by preventing its assembly in certain cell types. 44 After verifying the mTORC specificity of RAPA and ATP-competitive mTOR inhibitors, we used this strategy to dissect the function of RAPAsensitive and RAPA-resistant pathways in conventional DCs. RAPA-sensitive mTOR (mTORC1) promoted costimulatory CD80 and CD86 expression and reduced IL-12 secretion. RAPA inhibits phosphorylation of inhibitory residues on glycogen synthase kinase 3 leading to NF-kB p65 activation and increased IL-12 secretion after TLR4 ligation. 17, [19] [20] [21] 45 Our data support these findings where RAPA-sensitive mTORC1 suppresses IL-12 production. A recent study demonstrated a similar role for mTORC2 in DCs following LPS activation where rictor knockdown enhanced proinflammatory cytokine and reduced IL-10 secretion. However, elevated IL-12 secretion in these cells did not require NF-kB but was due to hyperactive FoxO1. 46 The present study identifies, for the first time, a RAPA-resistant mTORC1 pathway that is critical for controlling the immune regulatory properties of DCs and further elaborates on signaling events downstream of TLR4.
ATP-competitive mTOR inhibition promoted DC IL-10 and B7-H1 expression and enhanced STAT3 activation. Enhanced STAT3 activation and reduced SOCS3 expression were only seen following prolonged ATP-competitive mTOR inhibition. These data demonstrate that the kinetics of mTOR inhibition (short-term exposure vs long-term conditioning), in addition to the complexes being targeted, are critical to understanding the function of mTOR in DCs. Initial publications describing ATP-competitive mTOR inhibitors revealed, unexpectedly, that RAPA did not inhibit mTORC1 completely; however, ATP-competitive mTOR inhibitors fully inhibited residual, RAPA-resistant mTORC1. 13, 14 To our knowledge, the present report describes the first RAPAresistant mTOR pathway that is not dependent on RAPA-sensitive mTORC1. Contrastingly, RAPA produces the opposite effects, whereby B7-H1 and IL-10 are diminished. Raptor-deficient DCs lacking RAPA-sensitive and RAPA-resistant mTORC1 activity display reduced IL-10 production. 47 Extended exposure of rictor
DCs to RAPA was not sufficient to upregulate B7-H1 (data not shown). Our findings can therefore be ascribed to a novel, RAPAresistant mTORC1 pathway that is subordinate to RAPA-sensitive mTORC1 or to concomitant inhibition of RAPA-resistant mTORC1 and mTORC2. Our data highlight the distinct function of mTOR-containing complexes in DCs when compared with T cells. mTOR-deficient T cells show reduced STAT3 phosphorylation, 48 similarly to DCs exposed to short-term mTOR inhibition. 23 Our data show that extended ATP-competitive mTOR inhibitor conditioning reduces DC SOCS3 expression, but rictor deletion has no effect on SOCS3 in DCs. These apparent inconsistencies support how mTOR signaling occurs differentially in DCs and T cells.
Evidence is accumulating for a role of mTOR in DCs in shaping T-cell responses. Our data demonstrate that, although RAPA-sensitive mTORC1 promotes costimulatory molecule expression and Foxp3
-T eff proliferation, RAPA-resistant and rictorindependent mTOR reduces IL-10 secretion and restrains T reg induction by downregulating coinhibitory B7-H1. Interestingly, although DC B7-H1 expression was required for augmented T reg induction by Torin1-conditioned DCs, the only known receptor for B7-H1, PD-1, was not required. PD-1-independent B7-H1 activity has been reported, 49 and our data also suggest that unidentified B7-H1 receptors may exist. IL-1b was required for T reg induction and functioned additively with B7-H1 on Torin1-conditioned DCs. Neutralization of IL-1b (data not shown) and genetic deletion of B7-H1 also reduced T reg induction by RAPA-conditioned DCs but not control DCs, which suggests that other effects of mTORC1 inhibition are required that function collectively with IL-1b and B7-H1 to promote T reg induction.
ATP-competitive inhibition to target RAPA-resistant mTOR may be useful for the treatment of inflammatory disorders. mTORC2 signaling is required for Th1 and Th2 22 or only Th2 23 differentiation, and deletion of mTOR in T cells causes diversion to Foxp3 1 Tregs following stimulation. 48 Our data support the development of ATP-competitive mTOR inhibitors for clinical use, especially because similar findings regarding B7-H1 expression were obtained in human DC cultures and following administration of an ATP-competitive mTOR inhibitor to mice. Further development of ATP-competitive mTOR inhibitors will be required because some have brief half-lives, 26 and their in vivo pharmacology is poorly understood. Given the paradoxical enhancement of IL-12p70 17, 19, 45 and IL-1b 16, 18 production by RAPA-conditioned DCs and the reported pulmonary inflammation that can be associated with RAPA, 50 augmentation of DCderived IL-10 secretion and lack of increased IL-1b production by ATP-competitive mTOR inhibitors may mitigate untoward side effects of mTORC1 inhibition. Together, these studies demonstrate a novel, immune regulatory pathway mediated by RAPA-resistant mTOR downstream of TLR4 that is relevant for clinical applications of mTOR inhibition. For personal use only. on June 12, 2017 . by guest www.bloodjournal.org From
